Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Overview of attention for article published in Clinical Cancer Research, December 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter: 16 X users

patent: 6 patents

Readers on

mendeley: 40 Mendeley

So far, Altmetric has seen 25 X posts from 16 X users, with an upper bound of 136,378 followers.

RT @JBrosnanCashman: Exciting efficacy and biomarker data of HER3-Dxd from Dr. Pasi Jänne (@DanaFarber) at #ASCO21! For more from his grou…

Exciting efficacy and biomarker data of HER3-Dxd from Dr. Pasi Jänne (@DanaFarber) at #ASCO21! For more from his group, don't miss this recent #clinicaltrial published in @CCR_AACR. @DanaFarberNews https://t.co/Yibw5r3dsm

RT @filimasini: Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Ther…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 21 additional X posts.